These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 38493499)
1. Dual-Responsive Supramolecular Polymeric Nanomedicine for Self-Cascade Amplified Cancer Immunotherapy. Hu W; Ye B; Yu G; Yang H; Wu H; Ding Y; Huang F; Wang W; Mao Z Adv Sci (Weinh); 2024 May; 11(20):e2305382. PubMed ID: 38493499 [TBL] [Abstract][Full Text] [Related]
2. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622 [TBL] [Abstract][Full Text] [Related]
3. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy. Wang X; Yan B; Li H; Yuan J; Guo J; Wang S; Dai P; Liu X ACS Appl Mater Interfaces; 2024 Jun; 16(24):30671-30684. PubMed ID: 38843203 [TBL] [Abstract][Full Text] [Related]
4. Cancer immunogenic cell death via photo-pyroptosis with light-sensitive Indoleamine 2,3-dioxygenase inhibitor conjugate. Lu Y; Xu F; Wang Y; Shi C; Sha Y; He G; Yao Q; Shao K; Sun W; Du J; Fan J; Peng X Biomaterials; 2021 Nov; 278():121167. PubMed ID: 34624752 [TBL] [Abstract][Full Text] [Related]
5. Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway. Yang X; Zhang W; Jiang W; Kumar A; Zhou S; Cao Z; Zhan S; Yang W; Liu R; Teng Y; Xie J J Nanobiotechnology; 2021 Jun; 19(1):182. PubMed ID: 34127005 [TBL] [Abstract][Full Text] [Related]
6. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway. Liu D; Chen B; Mo Y; Wang Z; Qi T; Zhang Q; Wang Y Nano Lett; 2019 Oct; 19(10):6964-6976. PubMed ID: 31518149 [TBL] [Abstract][Full Text] [Related]
7. Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor. Huang Z; Wei G; Zeng Z; Huang Y; Huang L; Shen Y; Sun X; Xu C; Zhao C Theranostics; 2019; 9(19):5542-5557. PubMed ID: 31534502 [TBL] [Abstract][Full Text] [Related]
8. Ultra-small Janus nanoparticle-induced activation of ferroptosis for synergistic tumor immunotherapy. Wang J; Wang Z; Li L; Wang M; Chang J; Gao M; Wang D; Li C Acta Biomater; 2024 Jun; 181():362-374. PubMed ID: 38663684 [TBL] [Abstract][Full Text] [Related]
9. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy. Zhou L; Zhang P; Wang H; Wang D; Li Y Acc Chem Res; 2020 Sep; 53(9):1761-1772. PubMed ID: 32819102 [TBL] [Abstract][Full Text] [Related]
10. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. Sun J; Wan Z; Chen Y; Xu J; Luo Z; Parise RA; Diao D; Ren P; Beumer JH; Lu B; Li S Acta Biomater; 2020 Apr; 106():289-300. PubMed ID: 32004652 [TBL] [Abstract][Full Text] [Related]
11. A Hybrid Supramolecular Polymeric Nanomedicine for Cascade-Amplified Synergetic Cancer Therapy. Yang K; Qi S; Yu X; Bai B; Zhang X; Mao Z; Huang F; Yu G Angew Chem Int Ed Engl; 2022 Jul; 61(27):e202203786. PubMed ID: 35384193 [TBL] [Abstract][Full Text] [Related]
12. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects. Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460 [TBL] [Abstract][Full Text] [Related]
13. Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy. Yentz S; Smith D BioDrugs; 2018 Aug; 32(4):311-317. PubMed ID: 29980987 [TBL] [Abstract][Full Text] [Related]
14. Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation. Zhou Y; Ren X; Hou Z; Wang N; Jiang Y; Luan Y Nanoscale Horiz; 2021 Feb; 6(2):120-131. PubMed ID: 33206735 [TBL] [Abstract][Full Text] [Related]
15. Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy. Cheng K; Ding Y; Zhao Y; Ye S; Zhao X; Zhang Y; Ji T; Wu H; Wang B; Anderson GJ; Ren L; Nie G Nano Lett; 2018 May; 18(5):3250-3258. PubMed ID: 29683683 [TBL] [Abstract][Full Text] [Related]
16. Folated pH-degradable nanogels for the simultaneous delivery of docetaxel and an IDO1-inhibitor in enhancing cancer chemo-immunotherapy. Qiao H; Chen X; Chen E; Zhang J; Huang D; Yang D; Ding Y; Qian H; Feijen J; Chen W Biomater Sci; 2019 Jun; 7(7):2749-2758. PubMed ID: 30997445 [TBL] [Abstract][Full Text] [Related]
17. Light-Triggered PROTAC Nanoassemblies for Photodynamic IDO Proteolysis in Cancer Immunotherapy. Choi J; Park B; Park JY; Shin D; Lee S; Yoon HY; Kim K; Kim SH; Kim Y; Yang Y; Shim MK Adv Mater; 2024 Sep; 36(38):e2405475. PubMed ID: 38898702 [TBL] [Abstract][Full Text] [Related]
18. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model. Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143 [TBL] [Abstract][Full Text] [Related]
19. Chemo-Immunotherapy: Role of Indoleamine 2,3-Dioxygenase in Defining Immunogenic Versus Tolerogenic Cell Death in the Tumor Microenvironment. Johnson TS; Mcgaha T; Munn DH Adv Exp Med Biol; 2017; 1036():91-104. PubMed ID: 29275467 [TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway. Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]